Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.

Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Cartenì G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, Battelli N.

Cancers (Basel). 2019 Dec 30;12(1). pii: E84. doi: 10.3390/cancers12010084.

2.

Validation of RP-HPLC method to assess the compatibility of metoclopramide and midazolam intravenous mixture used in patients with cancer.

Sanogo S, Silimbani P, Gaggeri R, Rossi R, Elviri L, Maltoni M, Masini C.

Eur J Hosp Pharm. 2019 Nov;26(6):323-328. doi: 10.1136/ejhpharm-2018-001544. Epub 2018 May 15.

PMID:
31798855
3.

Evaluating the appropriateness of chemotherapy in a low-resource cancer centre in sub-Saharan Africa.

Serra P, Katabalo DM, Masalu N, Amadori D, Bugingo S, Foca F, Bravaccini S, Donati C, Bucchi L, Masini C.

Cancer Med. 2020 Jan;9(1):133-140. doi: 10.1002/cam4.2672. Epub 2019 Nov 13.

4.

Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study.

Buti S, Bersanelli M, Viansone A, Leonetti A, Masini C, Ratta R, Procopio G, Maines F, Iacovelli R, Ciccarese C, Vitale MG, De Giorgi U, Mucciarini C, Maruzzo M, Prati G, Lattanzi E, Ciammella P, Bruni A, Andreani S, D'Abbiero N.

Cancer Treat Res Commun. 2020;22:100161. doi: 10.1016/j.ctarc.2019.100161. Epub 2019 Sep 29.

5.

Explaining the aggressiveness of breast cancer in sub-Saharan African patients.

Bravaccini S, Bucchi L, Puccetti M, Ravaioli S, Tumedei MM, Serra P, Masini C, Kahima J, Masalu N, Amadori D.

J Clin Pathol. 2019 Oct;72(10):723-724. doi: 10.1136/jclinpath-2019-206071. Epub 2019 Aug 13. No abstract available.

PMID:
31409610
6.

Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM).

Vitale MG, Bracarda S, Cosmai L, Crocetti E, Di Lorenzo G, Lapini A, Mandressi A, Martorana G, Masini C, Montironi R, Ortega C, Passalacqua R, Porta C, Procopio G, Sepe P, Romano L, Pappagallo GL, Conti G, Guida M, Martignoni G, Nolè F, Pignata S, Gori S, Cartenì G.

Tumori. 2019 Jul;105(4_suppl):3-12. doi: 10.1177/0300891619853392.

PMID:
31264522
7.

A comparison between two educational methods in the rehabilitation of the microstomia in systemic sclerosis: a randomized controlled trial.

Uras C, Mastroeni S, Tabolli S, Masini C, Pallotta S, Teofoli P, Rocco G, Mazzanti C, Abeni D.

Clin Rehabil. 2019 Nov;33(11):1747-1756. doi: 10.1177/0269215519858395. Epub 2019 Jun 19.

PMID:
31216880
8.

The effect of a treatment delay on outcome in metastatic renal cell carcinoma.

Iacovelli R, Galli L, De Giorgi U, Porta C, Nolè F, Zucali P, Sabbatini R, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Buti S, Massari F, Masini C, Ricotta R, Biasco E, Lolli C, Gri N, Verri E, Miggiano C, Vitale MG, Tortora G.

Urol Oncol. 2019 Aug;37(8):529.e1-529.e7. doi: 10.1016/j.urolonc.2019.03.005. Epub 2019 Mar 29.

PMID:
30935843
9.

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.

Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL, De Giorgi U, Masini C, Bamias A, Garcia Del Muro X, Duran I, Powles T, Gamulin M, Zengerling F, Geczi L, Gedye C, de Ducla S, Fear S, Merseburger AS.

Eur Urol. 2019 Jul;76(1):73-81. doi: 10.1016/j.eururo.2019.03.015. Epub 2019 Mar 23.

10.

Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study.

Masini C, Vitale MG, Maruzzo M, Procopio G, de Giorgi U, Buti S, Rossetti S, Iacovelli R, Atzori F, Cosmai L, Vignani F, Prati G, Scagliarini S, Guida A, Berselli A, Pinto C.

Clin Genitourin Cancer. 2019 Feb;17(1):e150-e155. doi: 10.1016/j.clgc.2018.10.001. Epub 2018 Oct 10.

PMID:
30396828
11.

Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience.

Sbrana A, Biasco E, Paolieri F, Palesandro E, Caserta C, Iacovelli R, Detti B, Santini D, Mosca A, Morelli F, Fornarini G, De Giorgi U, Masini C, Galli L.

Anticancer Res. 2018 Aug;38(8):4913-4918. doi: 10.21873/anticanres.12807.

PMID:
30061269
12.

Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.

Vitale MG, Scagliarini S, Galli L, Pignata S, Lo Re G, Berruti A, Defferrari C, Spada M, Masini C, Santini D, Ciuffreda L, Ruggeri EM, Bengala C, Livi L, Fagnani D, Bonetti A, Giustini L, Hamzaj A, Procopio G, Caserta C, Sabbatini R.

PLoS One. 2018 Jul 6;13(7):e0199642. doi: 10.1371/journal.pone.0199642. eCollection 2018.

13.

The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.

Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C.

Anticancer Drugs. 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632.

PMID:
29846246
14.

Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?

Iacovelli R, De Giorgi U, Galli L, Zucali P, Nolè F, Sabbatini R, Fraccon AP, Basso U, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Pasini F, Masini C, Massari F, Buti S, Sava T, Sacco C, Ricotta R, Sperduti I, Tortora G, Porta C.

Clin Genitourin Cancer. 2018 Oct;16(5):355-359.e1. doi: 10.1016/j.clgc.2018.04.007. Epub 2018 May 7.

PMID:
29803346
15.

Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.

Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Cartenì G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, Vernieri C, Santini D, Sorarù M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, Verzoni E.

Clin Genitourin Cancer. 2018 Aug;16(4):e945-e951. doi: 10.1016/j.clgc.2018.03.014. Epub 2018 Apr 19.

PMID:
29753637
16.

Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy.

Damuzzo V, Russi A, Chiumente M, Masini C, Rebesco B, Gregis F, Nozza S, Pigozzo J, Chiarion-Sileni V, Palozzo AC.

J Oncol Pharm Pract. 2019 Jun;25(4):787-792. doi: 10.1177/1078155218755867. Epub 2018 Feb 14.

17.

Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients.

Farolfi A, Silimbani P, Gallegati D, Petracci E, Schirone A, Altini M, Masini C.

Oncotarget. 2017 Jun 16;8(46):81343-81349. doi: 10.18632/oncotarget.18527. eCollection 2017 Oct 6.

18.

Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging.

Iotti V, Ravaioli S, Vacondio R, Coriani C, Caffarri S, Sghedoni R, Nitrosi A, Ragazzi M, Gasparini E, Masini C, Bisagni G, Falco G, Ferrari G, Braglia L, Del Prato A, Malavolti I, Ginocchi V, Pattacini P.

Breast Cancer Res. 2017 Sep 11;19(1):106. doi: 10.1186/s13058-017-0899-1.

19.

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.

Iacovelli R, Cossu Rocca M, Galli L, De Giorgi U, Sabbatini R, Santoni M, Mosca A, Fornarini G, Massari F, Masini C, Bersanelli M, Biasco E, Lolli C, Guida A, Berardi R, Terrone C, Pastorino A, Ardizzoni A, Pinto C, Buti S, Nolè F, Tortora G.

Urol Oncol. 2017 Sep;35(9):541.e7-541.e13. doi: 10.1016/j.urolonc.2017.05.007. Epub 2017 May 29.

PMID:
28572027
20.

First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.

Buti S, Bersanelli M, Maines F, Facchini G, Gelsomino F, Zustovich F, Santoni M, Verri E, De Giorgi U, Masini C, Morelli F, Vitale MG, Sava T, Prati G, Librici C, Fraccon AP, Fornarini G, Maruzzo M, Leonardi F, Caffo O.

Clin Genitourin Cancer. 2017 Aug;15(4):e609-e614. doi: 10.1016/j.clgc.2016.12.024. Epub 2016 Dec 29.

PMID:
28108284
21.

Robotic i.v. medication compounding: Recommendations from the international community of APOTECAchemo users.

Yaniv AW, Orsborn A, Bonkowski JJ, Chew L, Krämer I, Calabrese S, de la Paz Pacheco Ramos M, Palombi A, Lim SW, Tabbara O, Masini C, Schierl R, Bufarini C, Peaty N, Paolucci D.

Am J Health Syst Pharm. 2017 Jan 1;74(1):e40-e46. doi: 10.2146/ajhp151027. Epub 2016 Dec 22.

PMID:
28007720
22.

Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions.

Casadei Gardini A, Tenti E, Masini C, Nanni O, Scarpi E, Valgiusti M, Restuccia S, Gallani ML, Palazzini S, Bianchini E, Menozzi S, Maugeri A, Amadori D, Minguzzi M, Frassineti GL.

Oncotarget. 2016 Jun 28;7(26):40719-40724. doi: 10.18632/oncotarget.8942.

23.

Reversible inactivation of rostral nucleus raphe pallidus attenuates acute autonomic responses but not their habituation to repeated audiogenic stress in rats.

Nyhuis TJ, Masini CV, Taufer KL, Day HE, Campeau S.

Stress. 2016;19(2):248-59. doi: 10.3109/10253890.2016.1160281. Epub 2016 Mar 21.

24.

Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review.

Leonetti A, Bersanelli M, Castagneto B, Masini C, Di Meglio G, Pellegrino B, Buti S.

Clin Genitourin Cancer. 2016 Aug;14(4):277-83. doi: 10.1016/j.clgc.2016.01.010. Epub 2016 Jan 28. Review.

PMID:
26899142
26.

Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis.

Guida A, Masini C, Milella M, Di Lorenzo G, Santoni M, Prati V, Porta C, Cosmai L, Donati D, del Giovane C, Mighali P, Sabbatini R.

Future Oncol. 2015;11(23):3159-66. doi: 10.2217/fon.15.256. Epub 2015 Nov 6.

PMID:
26544922
27.

Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma.

Iacovelli R, Santini D, Rizzo M, Felici A, Santoni M, Verzoni E, Masini C, Massari F, Calvani N, Mosca A, Procopio G.

Can Urol Assoc J. 2015 Jul-Aug;9(7-8):263-7. doi: 10.5489/cuaj.2377.

28.

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.

Salvi S, Casadio V, Conteduca V, Burgio SL, Menna C, Bianchi E, Rossi L, Carretta E, Masini C, Amadori D, Calistri D, Attard G, De Giorgi U.

Br J Cancer. 2015 May 12;112(10):1717-24. doi: 10.1038/bjc.2015.128. Epub 2015 Apr 21.

29.

Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.

Sternberg CN, Calabrò F, Bracarda S, Cartenì G, Lo Re G, Ruggeri EM, Basso U, Gasparini G, Ciuffreda L, Ferrari V, Bonetti A, Fea E, Gasparro D, Tassinari D, Labianca R, Masini C, Fly K, Zhang K, Hariharan S, Capaccetti B, Porta C.

Oncology. 2015;88(5):273-80. doi: 10.1159/000369256. Epub 2015 Jan 15.

PMID:
25592399
30.

The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.

Catania C, Maur M, Berardi R, Rocca A, Giacomo AM, Spitaleri G, Masini C, Pierantoni C, González-Iglesias R, Zigon G, Tasciotti A, Giovannoni L, Lovato V, Elia G, Menssen HD, Neri D, Cascinu S, Conte PF, Braud Fd.

Cell Adh Migr. 2015;9(1-2):14-21. doi: 10.4161/19336918.2014.983785.

31.

Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide.

Conteduca V, Burgio SL, Menna C, Carretta E, Rossi L, Bianchi E, Masini C, Amadori D, De Giorgi U.

Prostate. 2014 Dec;74(16):1691-6. doi: 10.1002/pros.22890. Epub 2014 Sep 27.

PMID:
25262981
32.

Environmental contamination by cyclophosphamide preparation: Comparison of conventional manual production in biological safety cabinet and robot-assisted production by APOTECAchemo.

Schierl R, Masini C, Groeneveld S, Fischer E, Böhlandt A, Rosini V, Paolucci D.

J Oncol Pharm Pract. 2016 Feb;22(1):37-45. doi: 10.1177/1078155214551316. Epub 2014 Sep 16.

PMID:
25227229
33.

Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.

Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S.

J Urol. 2015 Jan;193(1):41-7. doi: 10.1016/j.juro.2014.07.011. Epub 2014 Jul 18.

PMID:
25046616
34.

Automated preparation of chemotherapy: quality improvement and economic sustainability.

Masini C, Nanni O, Antaridi S, Gallegati D, Marri M, Paolucci D, Minguzzi M, Altini M.

Am J Health Syst Pharm. 2014 Apr 1;71(7):579-85. doi: 10.2146/ajhp130489.

PMID:
24644118
35.

Habituation of hypothalamic-pituitary-adrenocortical axis hormones to repeated homotypic stress and subsequent heterotypic stressor exposure in male and female rats.

Babb JA, Masini CV, Day HE, Campeau S.

Stress. 2014 May;17(3):224-34. doi: 10.3109/10253890.2014.905534. Epub 2014 Apr 10.

PMID:
24635729
36.

Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.

De Giorgi U, Rihawi K, Aieta M, Lo Re G, Sava T, Masini C, Baldazzi V, De Vincenzo F, Camerini A, Fornarini G, Burattini L, Rosti G, Moscetti L, Chiuri VE, Luzi Fedeli S, Ferrari V, Scarpi E, Amadori D, Basso U.

J Geriatr Oncol. 2014 Apr;5(2):156-63. doi: 10.1016/j.jgo.2014.01.001. Epub 2014 Jan 22.

PMID:
24495699
37.

Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.

De Giorgi U, Scarpi E, Sacco C, Aieta M, Lo Re G, Sava T, Masini C, De Vincenzo F, Baldazzi V, Camerini A, Fornarini G, Burattini L, Rosti G, Ferrari V, Moscetti L, Chiuri VE, Luzi Fedeli S, Amadori D, Basso U.

Clin Genitourin Cancer. 2014 Jun;12(3):182-9. doi: 10.1016/j.clgc.2013.11.005. Epub 2013 Nov 15.

PMID:
24369790
38.

Central gene expression changes associated with enhanced neuroendocrine and autonomic response habituation to repeated noise stress after voluntary wheel running in rats.

Sasse SK, Nyhuis TJ, Masini CV, Day HE, Campeau S.

Front Physiol. 2013 Nov 25;4:341. doi: 10.3389/fphys.2013.00341. eCollection 2013.

39.

Stressor-specific effects of sex on HPA axis hormones and activation of stress-related neurocircuitry.

Babb JA, Masini CV, Day HE, Campeau S.

Stress. 2013 Nov;16(6):664-77. doi: 10.3109/10253890.2013.840282. Epub 2013 Oct 1.

PMID:
23992519
40.

Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor.

Sabbatini R, Ortega C, Procopio G, Masini C, Galligioni E, Porta C.

Future Oncol. 2013 Jun;9(6):831-43. doi: 10.2217/fon.13.58. Review.

PMID:
23718304
41.

Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood.

Rossignoli F, Caselli A, Grisendi G, Piccinno S, Burns JS, Murgia A, Veronesi E, Loschi P, Masini C, Conte P, Paolucci P, Horwiz EM, Dominici M.

Biomed Res Int. 2013;2013:901821. doi: 10.1155/2013/901821. Epub 2013 Mar 31.

42.

Sex differences in activated corticotropin-releasing factor neurons within stress-related neurocircuitry and hypothalamic-pituitary-adrenocortical axis hormones following restraint in rats.

Babb JA, Masini CV, Day HE, Campeau S.

Neuroscience. 2013 Mar 27;234:40-52. doi: 10.1016/j.neuroscience.2012.12.051. Epub 2013 Jan 7.

43.

Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.

Masini C, Sabbatini R, Porta C, Procopio G, Di Lorenzo G, Onofri A, Buti S, Iacovelli R, Invernizzi R, Moscetti L, Aste MG, Pagano M, Grosso F, Lucia Manenti A, Ortega C, Cosmai L, Del Giovane C, Conte PF.

BJU Int. 2012 Sep;110(5):692-8. doi: 10.1111/j.1464-410X.2012.10946.x. Epub 2012 Feb 24.

44.

Auditory cortex lesions do not disrupt habituation of HPA axis responses to repeated noise stress.

Masini CV, Babb JA, Nyhuis TJ, Day HE, Campeau S.

Brain Res. 2012 Mar 14;1443:18-26. doi: 10.1016/j.brainres.2012.01.002. Epub 2012 Jan 13.

45.

Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.

Cianchini G, Lupi F, Masini C, Corona R, Puddu P, De Pità O.

J Am Acad Dermatol. 2012 Oct;67(4):617-22. doi: 10.1016/j.jaad.2011.11.007. Epub 2012 Jan 13.

PMID:
22243765
46.

Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.

Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, Silvestris N, Berardi R, Masini C, Calipari N, Ottaviani D, Catalano V, Badalamenti G, Giannicola R, Fabbri F, Venditti O, Fratto ME, Mazzara C, Latiano TP, Bertolini F, Petrelli F, Ottone A, Caroti C, Salvatore L, Falcone A, Giordani P, Addeo R, Aglietta M, Cascinu S, Barni S, Maiello E, Tonini G.

Ann Oncol. 2012 Aug;23(8):2072-7. doi: 10.1093/annonc/mdr572. Epub 2012 Jan 4.

47.

Cannabinoid receptor type 1 antagonism significantly modulates basal and loud noise induced neural and hypothalamic-pituitary-adrenal axis responses in male Sprague-Dawley rats.

Newsom RJ, Osterlund C, Masini CV, Day HE, Spencer RL, Campeau S.

Neuroscience. 2012 Mar 1;204:64-73. doi: 10.1016/j.neuroscience.2011.11.043. Epub 2011 Nov 28.

48.

Evidence for a lack of phasic inhibitory properties of habituated stressors on HPA axis responses in rats.

Masini CV, Day HE, Gray T, Crema LM, Nyhuis TJ, Babb JA, Campeau S.

Physiol Behav. 2012 Jan 18;105(2):568-75. doi: 10.1016/j.physbeh.2011.06.011. Epub 2011 Jun 25.

49.

Effects of voluntary wheel running on heart rate, body temperature, and locomotor activity in response to acute and repeated stressor exposures in rats.

Masini CV, Nyhuis TJ, Sasse SK, Day HE, Campeau S.

Stress. 2011 May;14(3):324-34. doi: 10.3109/10253890.2010.548013. Epub 2011 Mar 27.

50.

Lack of contextual modulation of habituated neuroendocrine responses to repeated audiogenic stress.

Nyhuis TJ, Sasse SK, Masini CV, Day HE, Campeau S.

Behav Neurosci. 2010 Dec;124(6):810-20. doi: 10.1037/a0021203.

Supplemental Content

Loading ...
Support Center